Australian Operations
Include All CSL Sites


Media Enquiries

Melanie Kerin
Senior Manager, Communications
Mobile: +61 (0) 417436329 

New PNG Snakebite Project to Improve Access to Antivenoms
A new partnership to help save the lives of people bitten by venomous snakes was launched today in Port Moresby. The ‘PNG Snakebite Partnership’ is a three-year project involving the National Department of Health, the Australian Government, Seqirus Pty Ltd, and the Charles Campbell Toxinology Centre, at the University of Papua New Guinea (UPNG). More.

Australians unprepared for potential dangers of venomous creatures this summer
Seqirus launches #NoStingsSummer campaign encouraging Aussies to take care and watch out for bites and stings this summer More.

Seqirus launches first over-the-counter offering, Nervoderm®
Seqirus has entered the over-the-counter market for the first time with a new Schedule 2, medicated patch, Nervoderm®. More.

Seqirus Manufacturing Director Recognised at 2017 Women in Industry Awards
Lisa Lamb, Manufacturing Director for Products of National Significance at biopharmaceutical company Seqirus has been named winner of the Manufacturing Excellence category at the 2017 Women in Industry Awards hosted in Melbourne on Thursday 22 June. More.

Afluria Quad™ – a four strain flu vaccine manufactured in Australia is now available
A quadrivalent flu vaccine manufactured by Seqirus locally in Melbourne, Australia is available for the 2017 Australian flu season for adults aged 18 years and older. More.

Majority of Aussies Unprepared for Close Encounters with Venomous Creatures
New research finds just one in five (20%) Aussies are familiar with emergency treatment for venomous bites and stings while younger Australians, aged under 25, are at greatest risk, showing the least amount of knowledge in treating bites and stings. More.

CSL completes Novartis influenza vaccine business acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million. More.

Update on Novartis influenza vaccines acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary approvals required to proceed with the acquisition of the influenza vaccines business of Novartis and that it is working with Novartis to bring forward the close date for the transaction. The Company also said the new CSL subsidiary resulting from the acquisition will be called Seqirus. More.

CSL Acquires Exclusive Rights to Influenza Treatment
CSL Limited (ASX:CSL) today announced it has acquired exclusive rights to commercialise the influenza treatment, RAPIVAB®, from US-based company, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX). More.



Media Enquiries

Melanie Kerin
Senior Manager, Communications, 
Mobile: +61 (0) 417436329 

LinkedIn Twitter Facebook Google+
© 2018 Seqirus